Key Points
- CTO James Liao sold 9,716 shares of Foxx Development (NASDAQ:FOXX) on Feb. 19 at an average price of $4.61, netting $44,790.76.
- Company financials: Foxx Development has a $29.17 million market cap, a one-year trading range of $1.71–$8.88, and reported a quarterly loss of ($0.62) EPS on $16.72 million in revenue.
- Institutional and analyst activity: Citadel Advisors bought 12,025 shares (~$57k) as a new position and institutions own 60.44% of the stock, while Weiss Ratings and the MarketBeat consensus rate FOXX as a "Sell".
Foxx Development Holdings Inc. (NASDAQ:FOXX - Get Free Report) CTO James Liao sold 9,716 shares of the firm's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $4.61, for a total transaction of $44,790.76. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Foxx Development Price Performance
NASDAQ FOXX opened at $4.16 on Wednesday. Foxx Development Holdings Inc. has a 1 year low of $1.71 and a 1 year high of $8.88. The company has a market capitalization of $29.17 million, a PE ratio of -1.84 and a beta of -0.28. The company has a fifty day moving average of $4.58 and a 200 day moving average of $4.53.
Foxx Development (NASDAQ:FOXX - Get Free Report) last released its quarterly earnings data on Friday, February 13th. The company reported ($0.62) earnings per share for the quarter. The business had revenue of $16.72 million during the quarter.
Institutional Investors Weigh In On Foxx Development
An institutional investor recently bought a new position in Foxx Development stock. Citadel Advisors LLC purchased a new position in shares of Foxx Development Holdings Inc. (NASDAQ:FOXX - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 12,025 shares of the company's stock, valued at approximately $57,000. Citadel Advisors LLC owned approximately 0.18% of Foxx Development at the end of the most recent quarter. Institutional investors own 60.44% of the company's stock.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Foxx Development in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of "Sell".
View Our Latest Stock Analysis on FOXX
About Foxx Development
(
Get Free Report)
Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company's core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.
Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
